Sector News

New COO engineers a management shake-up at Takeda

September 16, 2014
Life sciences
Takeda didn’t bring on non-Japanese COO Christophe Weber for nothing. The Osaka-based drugmaker, still faltering in the wake of its patent loss on diabetes champ Actos, was looking for a shake-up.
 
And now, as promised, the blueprints for a new, reorganized company structure are here. They include a new org chart, and a fresh set of top managers, including a replacement for the soon-to-be-former president of Millennium, Anna Protopapas.
 
Key to the change-up: Takeda will establish 5 so-called “regional business units” consisting of Japan Pharma, Emerging Markets, United States, Europe-Canada and Japan Consumer Healthcare, along with a pair of specialty business units for oncology and vaccines.
 
The Biotech Primer: An insider’s guide to the science driving the biotech and pharma industries
 
This 200-page book takes an in-depth look at the biotech industry and the science that drives it. Although the industry itself is constantly changing, these fundamental concepts upon which it is built will remain important for years to come – and decision-makers who understand these fundamentals will be better able to evaluate and predict new trends. Click here to buy today!
R&D will be realigned, too, to focus on a scaled-down list of therapeutic areas: central nervous system; cardiovascular and metabolic; gastroenterology; and oncology. Cambridge-based Millennium will become the new center of Takeda’s oncology efforts, with Christophe Bianchi stepping up to head the unit as Millennium’s Protopapas departs.
 
The way Takeda sees it, the revamp–which will be fully implemented by April 1 of next year, it figures–will help it zero in on its strategy, respond to changing market needs and capitalize on growth opportunities, which it could use after a 2013 that sunk it to a 15-year-low in net income.
 
Weber’s comments rang of recent moves from Takeda’s pharma peers, many of which have recently shed their non-core assets to double down on core areas of focus. “Our aspiration for Takeda is to be the best-in-class company in every aspect of our business,” he said in a statement.
 
That expanding in emerging markets ranks among the drugmaker’s top priorities is no surprise. Current CEO Yasuchika Hasegawa–slated to step down later this year and turn the reins over the Weber–has been working on bolstering the company’s presence in Latin America, and in July, Weber told Bloomberg the company needed to iron out its Indian operations.
 
These fast-growing markets, Takeda hopes, will help it rebound from the loss of Actos, a drug that once accounted for half the company’s U.S. revenues and 18% of its worldwide sales. Without it, the drugmaker has been foundering; in the first quarter of this year, it put up a mere 0.2% in sales growth with a top-line haul of ¥411.15 billion ($3.84 billion).
 
By Carly Helfand
 
comments closed

Related News

May 10, 2025

FDA approves Teal Health HPV screening test as an at-home alternative to the Pap smear

Life sciences

According to a study conducted by the company that included more than 600 participants, samples collected with the Teal Wand were shown to be just as accurate as those taken by a clinician during an office visit. About 94% of participants said they would opt for self-collection in the future, and 86% said they felt they would be more likely to stay up to date with cervical cancer screening if they could do it at home.

May 10, 2025

FDA appoints first chief AI officer as it looks to speed up reviews

Life sciences

Jeremy Walsh was named head of IT and AI, according to his post on LinkedIn. The move was first reported by Politico. Walsh previously held the role of chief technologist at Booz Allen Hamilton, managing AI- and cloud-based projects for 14 years at the consultancy.

May 10, 2025

Roquette announces a new organization following the acquisition of IFF Pharma Solutions

Life sciences

The new organization features two Business Groups that will rely on dedicated teams and assets to fully focus on meeting customer and market needs. Isabelle Bouvier is appointed as CEO of the Health & Pharma Solutions Business Group and Pascal Leroy as CEO of the Nutrition & Bioindustry Business Group. Béatrice Totel replaces Isabelle Bouvier as CFO of Roquette.

How can we help you?

We're easy to reach